Akero Therapeutics

two arrows pointing different directions

Avere goes public via reverse merger, pays $120M for Hansoh drug

Avere burst onto the scene by securing a public listing via a reverse merger with NextCure, while stocking its pipeline with an IL-23 drug from Hansoh.

Will Maddox Jul 14, 2026 6:00am

Graphic of two hands shaking under a red and purple light

Novo inks $4.7B Akero buyout to bag late-phase MASH prospect

Oct 9, 2025 8:21am

Apple Tree lawsuit says portfolio biotechs face collapse

Jun 30, 2025 3:21pm

Akero's stock doubles as midphase MASH trial hits the mark

Jan 27, 2025 8:31am

rocket snail slow leapfrog beat fast win jump over

As Madrigal lands MASH nod, what's next for biotechs in pursuit?

Mar 15, 2024 10:55am

Akero soars as liver scarring improves in longer MASH trial

Mar 4, 2024 6:30am